Ce-doped Li6Ln(BO3)3 (Ln = Y, Gd) Single crystals fibers grown by micro-pulling down method and luminescence properties

Ce3+-doped borate crystal fibers of Li6Gd(BO 3)3 (LGBO) and Li6Y(BO3)3 (LYBO) compositions are grown by the micro-pulling down (μ-PD) method for potential application in developing new neutron detectors. The ternary equilibrium diagram of Li2O-Gd2O3-B 2O3 is drawn and the preparations of homogeneous mixed LGBO and LYBO powders and growth conditions for single crystal fibers are discussed. Absorption, excitation and X-ray luminescence spectra are investigated. Absolute light yield derived from energy spectra and kinetic decay curves measured under α- and γ-scintillations of Ce 3+-doped LGBO and LYBO single crystal fibers is provided. © 2012 Elsevier B.V. All rights reserved

Model of demand for labor in the urfo pharmaceutical market

The purpose of the study is to comprehensive assessment of the structure of demand for labor in the pharmaceutical market of the URFO to build empirical functions of the demand for labor resources for pharmaceutical specialists with different qualifications.Цель исследования – комплексная оценка структуры спроса на труд на фармацевтическом рынке УрФО для построения эмпирических функций спроса на трудовые ресурсы для фармацевтических специалистов с разной квалификацией

Використання сучасних технологій в управлінні сучасним процесом на кафедрі ортопедичної стоматології з імплантологією

Обґрунтовується ідея підвищення якості підготовки фахівців шляхом цілеспрямованого регулярного корегування змісту навчання відповідно до вимог розвитку суспільства і формування ринку праці. Автори доводять, що використання сучасних інформаційних технологій, активних форм і методів навчання забезпечує розвиток самостійності студента

Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study

Background: Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments. Methods: The Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370. Findings: We enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2–11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no significant differences between treatments for primary outcomes for the 1586 patients with complete baseline and outcome data that were considered for primary analysis. Adjusted odds ratios for ventilation, inotropic support, or death were 1·09 (95% CI 0·75–1·58; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids and 0·93 (0·58–1·47; corrected p value=1·00) for glucocorticoids alone, versus intravenous immunoglobulin alone. Adjusted average hazard ratios for time to improvement were 1·04 (95% CI 0·91–1·20; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids, and 0·84 (0·70–1·00; corrected p value=0·22) for glucocorticoids alone, versus intravenous immunoglobulin alone. Treatment escalation was less frequent for intravenous immunoglobulin plus glucocorticoids (OR 0·15 [95% CI 0·11–0·20]; p<0·0001) and glucocorticoids alone (0·68 [0·50–0·93]; p=0·014) versus intravenous immunoglobulin alone. Persistent fever (from day 2 onward) was less common with intravenous immunoglobulin plus glucocorticoids compared with either intravenous immunoglobulin alone (OR 0·50 [95% CI 0·38–0·67]; p<0·0001) or glucocorticoids alone (0·63 [0·45–0·88]; p=0·0058). Coronary artery aneurysm occurrence and resolution did not differ significantly between treatment groups. Interpretation: Recovery rates, including occurrence and resolution of coronary artery aneurysms, were similar for primary treatment with intravenous immunoglobulin when compared to glucocorticoids or intravenous immunoglobulin plus glucocorticoids. Initial treatment with glucocorticoids appears to be a safe alternative to immunoglobulin or combined therapy, and might be advantageous in view of the cost and limited availability of intravenous immunoglobulin in many countries. Funding: Imperial College London, the European Union's Horizon 2020, Wellcome Trust, the Medical Research Foundation, UK National Institute for Health and Care Research, and National Institutes of Health

Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study

Background Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments. Methods The Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370. Findings We enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2–11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no significant differences between treatments for primary outcomes for the 1586 patients with complete baseline and outcome data that were considered for primary analysis. Adjusted odds ratios for ventilation, inotropic support, or death were 1·09 (95% CI 0·75–1·58; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids and 0·93 (0·58–1·47; corrected p value=1·00) for glucocorticoids alone, versus intravenous immunoglobulin alone. Adjusted average hazard ratios for time to improvement were 1·04 (95% CI 0·91–1·20; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids, and 0·84 (0·70–1·00; corrected p value=0·22) for glucocorticoids alone, versus intravenous immunoglobulin alone. Treatment escalation was less frequent for intravenous immunoglobulin plus glucocorticoids (OR 0·15 [95% CI 0·11–0·20]; p<0·0001) and glucocorticoids alone (0·68 [0·50–0·93]; p=0·014) versus intravenous immunoglobulin alone. Persistent fever (from day 2 onward) was less common with intravenous immunoglobulin plus glucocorticoids compared with either intravenous immunoglobulin alone (OR 0·50 [95% CI 0·38–0·67]; p<0·0001) or glucocorticoids alone (0·63 [0·45–0·88]; p=0·0058). Coronary artery aneurysm occurrence and resolution did not differ significantly between treatment groups. Interpretation Recovery rates, including occurrence and resolution of coronary artery aneurysms, were similar for primary treatment with intravenous immunoglobulin when compared to glucocorticoids or intravenous immunoglobulin plus glucocorticoids. Initial treatment with glucocorticoids appears to be a safe alternative to immunoglobulin or combined therapy, and might be advantageous in view of the cost and limited availability of intravenous immunoglobulin in many countries. Funding Imperial College London, the European Union's Horizon 2020, Wellcome Trust, the Medical Research Foundation, UK National Institute for Health and Care Research, and National Institutes of Health

Outcomes of surgical treatment for pituitary metastasis

We analyzed the outcomes of surgical treatment for pituitary metastasis (PM) based on 35 observations. We registered the best estimates of resection radicalism in patients with minor PM, its inconsiderable spread ascending and descending from the diaphragm of the sella turcica, slightly bleeding metastasis, and no invading to the cavernous sinus. Positive changes in the PM patients’ quality of life are chiefly associated with regressed visual impairment, local pain syndrome, and, to a lesser degree, oculomotor disorders. No post-operative regress or intensifying of hormonal impairments, such as diabetes insipidus and hypopituitarism, were seen. The age of patients, the time interval between the cancer diagnosis and the PM occurrence, control of the underlying disease, size of the tumour are the factors determining the life expectancy in PM patients

CHANGES IN VALUES OF MEAN AGE IN PATIENTS WITH PRIMARY DIAGNOSED MALIGNANCIES I N KRASNODAR REGION IN 2001-2015

Stages of Formation and functioning of population-based cancer registries (PBCR) in Krasnodar Region are presented now in this article. Introduction of this registries in Krasnodar Region had great impact on reliability of statistical information. We presented dynamic research results of mean age values in patients with malignancies in the region (according to PBCR). All indicators are considered regarding localization of malignant neoplasms, sex, rank places in dynamics for 15 years (2001-2015). We revealed authentic increase (p < 0,05) of average age in patients in general regarding all localizations (for 2,6 years). In female patients it has increased more (for 2,3 years) than in male patients (for 1,6 years). In the majority of localizations we observed authentic (p < 0,05) increase in middle age both in men (in 49% cases), and women (in 53,9%). Direct high correlation link of mean age and such indicators of health in the population as mean age and average life expectancy of the population in Krasnodar Region, with oncological incidence is noted

Construction of an Algorithm for Building Regions of Questionable Decisions for Devices Containing Gases in a Linear Multidimensional Space of Hazardous Factors

The issue of danger emanating from industrial devices with combustible gases has been considered in the linear multidimensional continuous space of dangerous factors. Dangerous factors are categorized into factors associated with industrial devices and the physical-chemical properties of gases that these devices contain. The actual existing combustible gases are characterized by numerical discrete properties such as molecular mass, specific heat of combustion, etc. An abstract model space of gases is represented in the space of dangerous factors by points whose coordinates are the physical-chemical properties of gases. Given the continuity of the space of dangerous factors, actual gases will be represented by individual points within this space or regions in which certain properties, for example temperature, density, volume, are continuously changing. In addition, there would be a large number of points at which the properties of gases are incompatible, that is such that are impossible for real gases. This has allowed us to consider the issue of danger emanating from combustible gases from some general positions. Thus, using the methodology of p-functions has made it possible to split the space of dangerous factors into dangerous and safe parts. It was also possible to identify the border regions in which the task of determining the hazard from a device is incorrect. That means that some variation of dangerous factors within the accuracy known about them leads to different, mutually exclusive conclusions about danger. Such areas are termed the regions of questionable decisions. It has been found that the regions of questionable decisions may be complex in shape and their size depends on the accuracy that is inherent in the quantitative values for dangerous factors. An algorithm for constructing regions of questionable decisions has been developed that could define whether a device containing gas belongs to a region of questionable decisions. It has been shown that determining whether a device is associated with a region of questionable decisions is a numerical problem with an unambiguous solutio